NEULAND LABORATORIES LTD.
NSE : NEULANDLABBSE : 524558ISIN
CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse
: Private
BSE7187.40203.55 (+2.91 % )
PREV CLOSE (Rs.) 6983.85
OPEN PRICE (Rs.) 6995.50
BID PRICE (QTY) 7187.00 (1 )
OFFER PRICE (QTY) 7203.45 (2 )
VOLUME 2805
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE7177.05 203.65 (+2.92 % )
PREV CLOSE(Rs.) 6973.40
OPEN PRICE (Rs.) 6973.40
BID PRICE (QTY) 7175.80 (2 )
OFFER PRICE (QTY) 7190.55 (5 )
VOLUME 17750
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 03-Apr-2024 | Neuland Laboratories informs about certificate | <p style="text-align: justify;">Neuland Laboratories has informed that it enclosed certificate as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2024, received from its Registrar and Share Transfer Agent, Kfin Technologies.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 04-Mar-2024 | Neuland Laboratories informs about analyst meet | <div>Neuland Laboratories has informed that the Company's management will be participating in the group analyst/ investor meetings as on March 7, 2024.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 26-Feb-2024 | Neuland Laboratories informs about issuance of letter of confirmation | <p style="text-align: justify;">Pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-RTAMB/P/CIR /2022/8 dated January 25, 2022, Neuland Laboratories has informed that the Company has approved issuance of Letter of Confirmation in lieu of share certificate(s) reported lost/misplaced by the shareholder(s), as per the details enclosed. </p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 13-Nov-2023 | Neuland Laboratories informs about transcript of earnings call | <div>Neuland Laboratories has informed that it enclosed the transcript of the Earnings call for the quarter and half year ended September 30, 2023, conducted on November 7, 2023. Also informed that this transcript of the call has been uploaded on its website. The weblink to access it: https://www.neulandlabs.com/investors/investor-updates/announcements/</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 20-Oct-2023 | Neuland Laboratories informs about loss of share certificate(s) | <p style="text-align: justify;">Pursuant to Regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Neuland Laboratories has informed that the shareholder(s) has reported to the Company about the loss of his/her share certificate(s) and has requested for issue of ‘Letter of Confirmation' in lieu of physical share certificate(s). The particulars relating to the loss of share certificate(s) are enclosed. </p><div>The above information is a part of company's filings submitted to BSE.</div> |
| 20-Jun-2023 | Neuland Laboratories informs about newspaper advertisement | <p style="text-align: justify;">Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, Neuland Laboratories has informed that it enclosed copies of newspaper advertisement regarding intimation of 39th Annual General Meeting of the Company to be held through Video Conferencing (VC) facility/Other Audio-Visual Means (OAVM), record date and other related information, as published in Financial Express and Andhra Prabha on June 20, 2023.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 07-Jun-2023 | Neuland Laboratories informs about newspaper publication | <p style="text-align: justify;">Neuland Laboratories has informed that it enclosed a copy of the Notice published on June 7, 2023 in Financial Express and Andhra Prabha pertaining to equity shares liable to be transferred to the Investor Education and Protection Fund pursuant to Section 124(6) of the Companies Act, 2013 read with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.</p><div>The above information is a part of company's filings submitted to BSE.</div> |
| 29-May-2023 | Neuland Laboratories informs about analyst meet | <div style="text-align: justify;">Neuland Laboratories has informed that the Company's management will be participating in the investor conferences / group investor meetings as on June 1, 2023.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 27-May-2023 | USFDA completes inspection at Unit 3 manufacturing facility of Neuland Laboratories | <p style="text-align: justify;">United States Food and Drug Administration (USFDA) has completed inspection in Neuland Laboratories' Unit 3 manufacturing facility, located at Gaddapotharam village, Jinnaram, Sangareddy District, from May 22, 2023 to May 26, 2023. The inspection has been concluded with 3 observations (minor) given under form 483, which are relating to procedures.</p><p style="text-align: justify;">Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry's chemistry needs.</p><div style="text-align: justify;"><br></div> |
| 04-May-2023 | Neuland Laboratories submits analyst meet intimation | <div style="text-align: justify;">Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, Neuland Laboratories has informed that it enclosed the schedule of Q4 and full year FY 2023 Earnings Call details.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
